+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Neocarzinostatin: a phase I clinical trial with five-day intermittent and continuous infusions

Neocarzinostatin: a phase I clinical trial with five-day intermittent and continuous infusions

Cancer 44(4): 1182-1188

Neocarzinostatin, a polypeptide antibiotic, was administered by both continuous and intermittent intravenous infusion to 76 patients with a variety of malignant diseases. Doses ranged from 500 to 6500 units/m2 X 5 days. With levels greater than or equal to 1800 units/m2, bone marrow suppression (particularly thrombocytopenia) was the dose-limiting toxicity. Delayed bone marrow recovery was less dose-dependent and occurred in 58% of initial treatment courses in solid tumor patients. Allergic reactions were more frequent with intermittent than with continuous infusions (20% vs. 2% of courses). No complete or partial remissions were observed among solid tumor patients although clinical improvement was noted in one patient with mycosis fungoides and one patient with multiple myeloma. One complete and two partial remissions were noted among 21 patients with acute leukemia. There was one complete remission in a patient with chronic leukemia. Leukemic patients on intermittent therapy evidenced greater change in bone marrow cellularity than those treated by continuous infusion. Although neocarzinostatin has some activity in the treatment of acute leukemia, continuous infusion offers no advantage over intermittent therapy.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 040780017

Download citation: RISBibTeXText

PMID: 159119

DOI: 10.1002/1097-0142(197910)44:4<1182::aid-cncr2820440403>3.0.co;2-b

Related references

Metoclopramide as intermittent and continuous infusions in critically ill patients: a pilot randomized clinical trial. Journal of Comparative Effectiveness Research 6(2): 127-136, 2017

Continuous Versus Intermittent Vancomycin Infusions in Infants: A Randomized Controlled Trial. Pediatrics 143(2):, 2019

Neocarzinostatin a phase ii clinical trial. Cancer Treatment Reports 65(7-8): 699-702, 1981

Neocarzinostatin: report of a phase II clinical trial. Cancer Treatment Reports 65(7-8): 699-701, 1981

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet. Oncology 15(6): 631-639, 2014

Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effects. Journal of Biological Response Modifiers 9(6): 538-545, 1990

A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia. Leukemia 7(10): 1500-1503, 1993

A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. Cancer ChemoTherapy and Pharmacology 30(4): 297-302, 1992

Can intermittent androgen deprivation be an alternative to continuous androgen withdrawal in patients with PSA-relapse? First results of the randomized prospective phase-III clinical trial EC 507. Journal of Urology 169(4 Suppl.): 396, 2003

Tri glycerides free fatty acids and cholesterol levels in serum of neo nates receiving chronic lipid infusions controlled trial of continuous and intermittent regimens. Clinical Research 31(1): 136A, 1983

Comparison of continuous versus intermittent infusions of terlipressin for the control of acute variceal bleeding in patients with portal hypertension: An open-label randomized controlled trial. Indian Journal of Gastroenterology 37(4): 313-320, 2018

Phase II trial of continuous drug infusions in advanced ovarian carcinoma: acivicin versus vinblastine. Investigational new Drugs 7(2-3): 255-260, 1989

Comparison of continuous and intermittent bolus infusions of metoclopramide during 5-day continuous intravenous infusion with cisplatin. European Journal of Cancer 27(6): 729-732, 1991

The efficacy of automated intermittent boluses for continuous femoral nerve block: a prospective, randomized comparison to continuous infusions. Journal of Clinical Anesthesia 25(4): 281-288, 2013

Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. Bmc Infectious Diseases 11: 181, 2011